The contract guarantees Eckert & Ziegler a one-time payment of EUR 10 million and additional royalties on Ac-225 sales. For Eckert & Ziegler the licence and collaboration agreement is an important ...
AC-225 is suitable for applications with up to 30,000 users across a modular 2,000 doors, allowing maximum flexibility for securing a growing enterprise. Each AC-225 Access Control Unit (ACU) supports ...
This publication includes existing experiences, lessons learned, challenges and future developments in the production of Ac-225 radiopharmaceuticals for Targeted Alpha Therapy (TAT). This publication ...
Eckert & Ziegler will provide high-quality Ac-225 to support GlyTherix’s clinical research and development activities on innovative alpha radiotherapeutics. In December 2024 Eckert & Ziegler ...
Under the terms of the agreement, ITM will supply the therapeutic medical radioisotope, Ac-225, produced by Actineer™ Inc, ITM's joint venture company with Canadian Nuclear Laboratories, for use in ...
Supply constraints have made Ac-225 a highly-sought asset for targeted radiotherapy initiatives, the analyst, who has a Buy ...
Actinium leads the industry in the application of the alpha-particle emitter actinium-225 (Ac-225), which is the most potent medical-grade radioisotope currently available. Its radiation power is ...
With extensive industry leadership experience, Mr. Oliverio is poised to drive Actineer’s global expansion in Actinium-225 (Ac-225) production. Mr. Oliverio joins Actineer with over three ...
Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...
The contract guarantees Eckert & Ziegler a one-time payment of EUR 10 million and additional royalties on Ac-225 sales. For Eckert & Ziegler the licence and collaboration agreement is an important ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback